Journals / The Turkish Journal of Ear Nose and Throat / 2021 / Cilt: 31 - Sayı: 3

Oncological and Functional Outcomes of Supracricoid Partial Laryngectomy

Pages
75–80
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Supracricoid partial laryngectomy with Cricohyoidoepiglotopexy and Cricohyoidopexy had satisfactory oncological outcomes, and laryngeal function was preserved by rebuilding the neolarynx.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to review the oncological outcomes of T1-T4 glottic or supraglottic tumor patients who underwent supracricoid partial laryngectomy in our clinic.
📊
Key Findings & Data:Material and Methods: A total of 43 patients with laryngeal squamous cell carcinoma who underwent supracricoid partial laryngectomy between January 2014 and December 2016 in the Otorhinolaryngology Department of Istinye University Hospital were retrospectively analyzed.
💡
Conclusion & Impact:Conclusion: Supracricoid partial laryngectomy with Cricohyoidoepiglotopexy and Cricohyoidopexy had satisfactory oncological outcomes, and laryngeal function was preserved by rebuilding the neolarynx.
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to review the oncological outcomes of T1-T4 glottic or supraglottic tumor patients who underwent supracricoid partial laryngectomy in our clinic. Material and Methods: A total of 43 patients with laryngeal squamous cell carcinoma who underwent supracricoid partial laryngectomy between January 2014 and December 2016 in the Otorhinolaryngology Department of Istinye University Hospital were retrospectively analyzed. Postoperative data of these patients regarding surgical margin, nasogastric feeding tube removal time, decannulation time, postoperative radiotherapy, local regional recurrence, and distant metastases were recorded. Results: Cricohyoidoepiglotopexy was applied to 16 patients by preserving both arytenoids and applied to 7 patients with a single arytenoid; Cricohyoidopexy was applied to 14 patients with both arytenoids preserved, and 6 patients were treated with a single arytenoid. The five-year survival was compared for Cricohyoidopexy/Cricohyoidoepiglotopexy with single arytenoid to double arytenoid preservation and found to be 80%-76% (p=0.56). The mean 5-year survival was 88% in the post-operative radiotherapy group, and 86% in the non- radiotherapy group. The study compared patients with Cricohyoidopexy/Cricohyoidoepiglotopexy with a single arytenoid to those with double arytenoid preservation; the mean decannulation time was 54.23±34.12 to 35.62±27.08 (p=0.05). Postoperative radiotherapy prolonged the decannulation time (51.16±38.5 versus 32.68±20.1; p=0.043). The duration of nasogastric tube placement in the Cricohyoidopexy/Cricohyoidoepiglotopexy with a single arytenoid group was 50.3±14.3 and double arytenoid preservation was 35.17±32.9 (p=0.088). Nasogastric tube removal time was 53.29±50.2 in the post-operative radiotherapy group and was 30.24±16.8 in patients who did not receive post-operative radiotherapy (p=0.040). Conclusion: Supracricoid partial laryngectomy with Cricohyoidoepiglotopexy and Cricohyoidopexy had satisfactory oncological outcomes, and laryngeal function was preserved by rebuilding the neolarynx.

🔖

Cite This Article

YILMAZ, E., ASLAN, İ., KESİMLİ, M. C., YAĞCI, İ. (2022). Oncological and Functional Outcomes of Supracricoid Partial Laryngectomy. The Turkish Journal of Ear Nose and Throat, Cilt: 31 - Sayı: 3, 75–80. https://ajindex.com/articles/597888

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin 2017;67(1):31-50. American Cancer Society. Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years. Am Cancer Soc 2019;2019:2015- 7. Ciolofan MS, Vlăescu AN, Mogoantă CA, Ioniță E, Ioniță I, Căpitănescu AN, et al. Clinical, Histological and Immunohistochemical Evaluation of Larynx Cancer. Curr Health Sci J 2017;43(4):367-375.
  2. Gallo A, Manciocco V, Simonelli M, Pagliuca G, D’Arcangelo E, De Vincentiis M. Supracricoid partial laryngectomy in the treatment of laryngeal cancer: univariate and multivariate analysis of prognostic factors. Arch Otolaryngol Neck Surg 2005;131(7):620-5. Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol 2006;7(9):747-55.
  3. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24(22):3693- 704. Weinstein GS, El-Sawy MM, Ruiz C, Dooley P, Chalian A, El-Sayed MM, et al. Laryngeal preservation with supracricoid partial laryngectomy results in improved quality of life when compared with total laryngectomy. Laryngoscope 2001;111(2):191-9.
  4. Schindler A, Favero E, Nudo S, Albera R, Schindler O, Cavalot AL. Long-term voice and swallowing modifications after supracricoid laryngectomy: objective, subjective, and self-assessment data. Am J Otolaryngol 2006;27(6):378-83.
  5. Gillespie MB, Brodsky MB, Day TA, Lee F, Martin-Harris B. Swallowing-related quality of life after head and neck cancer treatment. Laryngoscope 2004;114(8):1362-7.
  6. Majer H, Rieder W. Technique de laryngectomie permettant de conserver la permeabilite’respiratoire la cricohyoido-pexie. Ann Otolaryngol Chir Cervicofac 1959;76:677-83.
  7. Edge SB, Edge SB. AJCC Cancer Staging Manual 8th Ed. Springer; 2017.
  8. Nakayama M, Laccourreye O, Holsinger FC, Okamoto M, Hayakawa K. Functional organ preservation for laryngeal cancer: past, present and future. Jpn J Clin Oncol 2012;42(3):155-60.
  9. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. National Comprehensive Cancer Network. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23. doi: 10.6004/jnccn.2013.0113. Erratum in: J Natl Compr Canc Netw 2013;11(12):1458. Caicedo-Granados E, Beswick DM, Christopoul